Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Net Cash Flow (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Net Cash Flow for 7 consecutive years, with $105.5 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 60.74% to $105.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299.5 million through Dec 2025, up 111.9% year-over-year, with the annual reading at $299.5 million for FY2025, 111.9% up from the prior year.
  • Net Cash Flow hit $105.5 million in Q4 2025 for Harmony Biosciences Holdings, up from $100.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $105.5 million in Q4 2025 to a low of -$87.5 million in Q1 2021.
  • Historically, Net Cash Flow has averaged $26.2 million across 5 years, with a median of $26.9 million in 2022.
  • Biggest five-year swings in Net Cash Flow: crashed 285.85% in 2021 and later skyrocketed 874.83% in 2024.
  • Year by year, Net Cash Flow stood at $44.6 million in 2021, then tumbled by 139.37% to -$17.6 million in 2022, then increased by 26.4% to -$12.9 million in 2023, then soared by 607.89% to $65.6 million in 2024, then surged by 60.74% to $105.5 million in 2025.
  • Business Quant data shows Net Cash Flow for HRMY at $105.5 million in Q4 2025, $100.9 million in Q3 2025, and $57.1 million in Q2 2025.